COVID-19

COVID-19 changed the personal and professional lives of all pharmacy workforce members. But what now?

In older postmenopausal women, leukocyte count was found to be an independent predictor of long COVID symptom severity, highlighting its potential for use as a novel symptom biomarker.

New results shed light on the ineffectiveness of the combination antiviral therapy in patients vaccinated against COVID-19.

The test results are available in as little as 20 minutes.

New data from the longest known trial of pediatrics and adolescents in the postacute phase of COVID-19 show they are at a heightened risk of gastrointestinal tract symptoms.

Emerging data indicate that COVID-19 is also characterized by inflammation present in the heart and other organs

Investigators noted that the differences between the 3 respiratory infections were not as pronounced during the 2023-2024 season.

Through similar targeting of the RdRp enzyme, these treatments could offer groundbreaking new options for patients with COVID-19 if proven effective in real-world trials.

Patients recovering from COVID-19 and caregivers reported how some social determinants of health were helpful in their recovery, while others led to difficult social and mental challenges.

Engaging with the community, providing transparent information to patients, and using noncoercive methods of encouragement are strategies to reduce COVID-19 vaccine hesitancy.

The finding could help better treat patients with long COVID, as pharmacists and treatment providers can look out for ME/CFS symptoms.

Some patients treated with prolonged courses of oral nirmatrelvir/ritonavir experienced long COVID symptom improvements, while others reported little to no changes in their symptoms.

COVID-19 survivors deemed the most highly impacted and fearful also reported the lowest health-related quality of life scores, indicating an association.

The pandemic’s aftermath left lasting tensions in health care.

Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.

Study results show that the updated BNT162b2 XBB vaccine is effective in preventing hospitalizations or emergency department visits associated with COVID-19 complications.

Patient education on the risks of the long-term illness can help overcome vaccine hesitancy.

The conversation of VLR has sparked a discussion as to whether or not other COVID-19 treatment agents are associated with a surge in symptoms and if so, how those agents compare with the rebound effect of nirmatrelvir/ritonavir.

The combination vaccine candidates will be evaluated in 2 separate phase 1/2 clinical trials.

By identifying patients at high risk for progressing to severe disease and counseling them on their treatment options, pharmacists empower patients to make informed decisions about their treatment.

The decline was attributed to continued adherence to infection prevention and control measures.

The Act is set to end at the end of 2024, which will affect pharmacists’ abilities to administer COVID-19 tests, vaccines, and treatment that are distributed by the federal government.

Evidence suggests that precautionary measures in elementary schools were able to effectively mitigate large increases in disease transmission.

Severity of a COVID-19 illness could be determined by examining autoantibodies in the nasal cavity, allowing more personalized treatment protocols.

High COVID-19 hospital caseload strain led to increases in inpatient adverse events among patients both with and without SARS-CoV-2 infection.

Though both vaccines remain effective at preventing severe illness, Moderna’s mRNA-1273.222 vaccine was found to be significantly more effective among adults with underlying medical conditions.

In children aged 12, 18, and 24 months, there was no association between maternal COVID-19 exposure and abnormal scores on a neurodevelopment screening.

Despite suggestions to the contrary in previously conducted small clinical trials, montelukast did not provide benefit in patients with COVID-19 symptoms.

The clinical hold is a result of a reported case of motor neuropathy in a phase 2 trial participant.